The year in cardiovascular medicine 2022:the top 10 papers in heart failure and cardiomyopathies

[Figure: see text

Reverse Cardio-Oncology:Cancer Development in Patients With Cardiovascular Disease

This review focuses on reverse cardio‐oncology and highlights clinical studies, meta‐analyses, and cohorts that have evaluated cancer risk in patients with cardiovascular disease and the risk associated with treatments of cardiovascular disease. In addition, this article summarizes mechanisms of actions that mediate the cross-talk between cancer and cardiovascular disease

Diagnostic recommendations and phenotyping for heart failure with preserved ejection fraction:knowing more and understanding less?

This article refers to 'Diagnostic scores predict morbidity and mortality in patients hospitalised for heart failure with preserved ejection fraction' by F.H. Verbrugge et al., published in this issue on pages xxx

The year in cardiovascular medicine 2021:heart failure and cardiomyopathies

In the year 2021, the universal definition and classfication of heart failure (HF) was published that defines HF as a cli-cal syndrome with symptoms and/or signs caused by a cardiac abnormality and corroborated by elevated natriuretic peptide levels or objective evidence of cardiogenic congestion. This definition and the classification of HF with reduced ejection fraction (HFrEF), mildly reduced, and HF with pre-served ejection fraction (HFpEF) is consistent with the 2021 ESC Guidelines on HF. Among several other new recommendations, these guidelines give a Class I indication for the use of the sodium-glucose co-transporter 2 (SGLT2) inhibitors dapagliflozin and empagliflozin in HFrEF patients. As the first evidence-based treatment for HFpEF, in the EMPEROR-Preserved trial, empagliflozin reduced the composite endpoint of cardiovascular death and HF hospitalizations. Several reports in 2021 have provided novel and detailed analyses of device and medical therapy in HF, especially regarding sacubitril/valsartan, SGLT2 inhibitors, mineralocorticoid receptor antagonists, ferric carboxymal-tose, soluble guanylate cyclase activators, and cardiac myosin activators. In patients hospitalized with COVID-19, acute HF and myocardial injury is quite frequent, whereas myocarditis and long-term damage to the heart are rather uncommon.</p